# Tirzepatide: Two Receptors, and the Same Withdrawal Curve > Tirzepatide: Research Overview — Metabolic & Weight Research Peptides — Brand My Peptides — A reference-desk entry on tirzepatide (Mounjaro, Zepbound) among Metabolic & Weight research peptides: what SURMOUNT-1, SURMOUNT-5 and SURPASS-2 measured on treatment, and what the SURMOUNT-4 randomised withdrawal recorded after it stopped. **02 / METABOLIC & WEIGHT RESEARCH** The first approved dual incretin agonist, and the compound that beat semaglutide head to head on weight. Its own withdrawal study reported the divergence the class keeps producing: continuation kept working, and stopping did not hold. ## The short version Tirzepatide (Mounjaro, Zepbound) is a single manufactured peptide that switches on two different gut-hormone receptors at once — GIP and GLP-1 — where semaglutide switches on one. Pressing both levers produced larger weight and blood-sugar changes in trials than pressing the GLP-1 lever alone. It is given once a week by injection and works the same way at the level a reader cares about: hunger falls, meals end earlier, food intake drops, and weight follows. The stomach also empties more slowly, which explains most of the nausea people describe. On the question this desk is built around, tirzepatide has a direct answer rather than an inferred one. A dedicated withdrawal study took people who had already lost weight on the compound and randomly moved some of them to placebo. The ones who continued kept losing. The ones who stopped regained. Nothing on this page is advice, and no quantity described here is a recommendation for any person. ## What it is Tirzepatide is a synthetic peptide built on the native GIP sequence. A fatty diacid attached through a linker gives it high albumin affinity and extended exposure. The design supports long-acting dual agonism with one molecule rather than combining two separate compounds. It is the first approved dual incretin agonist. Its approved indications cover type 2 diabetes mellitus, chronic weight management in adults with obesity or with overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnoea in adults with obesity. All approved formulations are prescription-only. The StatPearls chapter confirms the dual GIP and GLP-1 mechanism, the type 2 diabetes approval and the fact that it is not approved for type 1 diabetes [8]. In the literature it appears as LY3298176, and informally as a twincretin or dual incretin mimetic. GIP and GLP-1 receptor agonists are not specifically listed as prohibited in sport under the current anti-doping code, a status that changes by list revision rather than by research summary. ## How it works Two receptors, one molecule. Tirzepatide activates the GIP receptor and the GLP-1 receptor simultaneously. Engaging both enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite and food intake — the same list as a selective GLP-1 agonist, but with larger glycaemic and weight effects across the trial programme. The interesting part of the pharmacology is that GIP had a poor reputation as a target on its own. Native GIP signalling in isolation had underwhelmed in metabolic research, and the working explanation for the combination's performance is that GIP receptor activation contributes something — in adipose handling and in central appetite signalling — that only becomes visible when GLP-1 signalling is running alongside it. For the discontinuation question, the architecture changes the magnitude but not the logic. Two receptors held open by a circulating agonist is still an occupancy mechanism. Nothing in the published pharmacology describes a durable structural change to appetite regulation that would survive the molecule's departure, and the withdrawal data are consistent with that reading rather than in tension with it. ## What the research shows **Weight, against placebo.** SURMOUNT-1 was a 72-week phase 3 double-blind randomised controlled trial in 2,539 adults with obesity — BMI of 30 or more, or 27 or more with a weight-related complication — and without diabetes. Mean weight change at week 72 was -15.0% at the 5 mg dose, -19.5% at 10 mg and -20.9% at 15 mg, against -3.1% with placebo. The most common adverse events were gastrointestinal, mostly mild to moderate, and occurred primarily during dose escalation [10]. **Weight, against semaglutide.** SURMOUNT-5 was a phase 3b open-label head-to-head trial in 751 adults with obesity but without type 2 diabetes, randomising participants to the maximum tolerated dose of tirzepatide (10 or 15 mg) or of semaglutide (1.7 or 2.4 mg), once weekly for 72 weeks. Least-squares mean weight change at week 72 was -20.2% with tirzepatide against -13.7% with semaglutide (P<0.001), with a greater reduction in waist circumference and higher proportions reaching the 10%, 15%, 20% and 25% weight-loss thresholds [1]. **Glycaemia.** SURPASS-2, an open-label 40-week phase 3 trial in 1,879 adults with type 2 diabetes, compared once-weekly tirzepatide at 5, 10 and 15 mg against semaglutide 1 mg. Estimated HbA1c reductions were 2.01, 2.24 and 2.30 percentage points against 1.86 with semaglutide — noninferior and superior at all doses — with greater body-weight reductions as well (treatment differences of -1.9, -3.6 and -5.5 kg) [11]. **Targeted safety analysis.** A systematic review and meta-analysis of nine randomised controlled trials covering 9,871 participants examined two specific signals in type 2 diabetes and obesity. Against controls — basal insulin, selective GLP-1 receptor agonists, or placebo — tirzepatide was not associated with a statistically significant increase in pancreatitis (RR 1.46; 95% CI 0.59-3.61), but was associated with a significantly increased risk of the composite of gallbladder or biliary disease (RR 1.97; 95% CI 1.14-3.42), with no significant increase in cholelithiasis, cholecystitis or biliary disease taken individually [9]. As with every entry on this desk, each of those numbers carries a timestamp inside a period of continuing treatment. ## Reported effects, cautions & safety The block that follows is **anecdotal, not clinical evidence** — patient interviews, community reporting and unadjudicated post-market description, recorded without doses and without clinical verification. *Frequently reported as benefits.* The dominant theme is a quieting of intrusive food-related thought. Reporters describe forgetting to eat because the drive to seek food fades. *Commonly reported:* more energy and less sluggishness as weight declines, plus improved mood and confidence. *Sometimes reported:* better sleep, reduced snoring, less joint pain, easier movement and self-noticed changes in metabolic readings. *Frequently reported as adverse or mixed.* Nausea leads, especially after escalation, usually fading as exposure continues. *Commonly reported:* alternating constipation and loose stools, injection-site pain or redness, and weight-loss plateaus. *Sometimes reported:* sulfur-smelling burps, altered taste, food aversions, concern about muscle loss and hair thinning attributed by reporters to rapid weight reduction. **The documented cautions come from trials, labelling and pharmacovigilance.** - **Gastrointestinal intolerance during escalation.** Dose-dependent nausea, vomiting, diarrhoea, constipation and decreased appetite are the most common adverse effects, mostly mild to moderate and concentrated during escalation [10]. - **Thyroid C-cell tumours and MEN-2.** Prescribing information carries a boxed warning based on rodent data, with contraindications for relevant personal or family history [8]. - **Pancreatitis and biliary disease.** A targeted meta-analysis found no statistically significant pancreatitis increase but did find an increased gallbladder-or-biliary composite (RR 1.97; 95% CI 1.14-3.42) [9]. - **Interaction cautions.** Hypoglycaemia risk rises with insulin or a sulfonylurea. Delayed gastric emptying matters for perioperative aspiration and for absorption of oral hormonal contraceptives. Severe gastrointestinal fluid loss can produce dehydration and acute kidney injury. - **Lean-mass loss.** Research is still defining how much rapid weight reduction changes skeletal muscle and whether that change affects function. - **Discontinuation.** Comparative evidence summarized in the corpus found more adverse-event discontinuation with tirzepatide than with a comparator incretin, driven largely by gastrointestinal tolerability. - **Sponsor funding.** Much of the highest-quality efficacy evidence comes from manufacturer-run trials, a standard feature of novel-drug development that still belongs in an assessment of the evidence base. ## Where it sits in the discontinuation record Tirzepatide contributes a direct demonstration on this desk because its withdrawal study was designed to produce one clear contrast. **The design.** Participants received tirzepatide during an open-label lead-in and lost weight. Only then were they randomised — to continue the compound or to switch to placebo — and followed. Both arms therefore started from the same reduced weight, on the same background regimen, with the same trial-level attention. The decisive difference across randomisation was whether the molecule remained present. **The result.** The arms diverged. Participants switched to placebo regained weight; participants who continued went on losing. Pooled withdrawal analyses across the incretin class summarized in the corpus report the same shape and describe regain as related to the amount initially lost. Regain also tracked with worsening cardiometabolic risk factors, consistent with the semaglutide extension's account of improvements reverting alongside weight. **The second route to discontinuation.** Not all stopping is planned. Gastrointestinal intolerance drives much of the discontinuation recorded across this class, and comparative evidence summarized in the corpus found more adverse-event discontinuation with tirzepatide than with a comparator incretin. A withdrawal curve is therefore not only a hypothetical about an elective decision; in the trial record, tolerability can also end treatment. **What the record supports.** The metabolic benefits documented in SURMOUNT-1 [10], SURMOUNT-5 [1] and SURPASS-2 [11] were measured with treatment continuing. That is a statement about trial evidence and its limits, not a recommendation about anyone's regimen. This desk describes withdrawal only as a condition investigators deliberately created in order to measure it, publishes no schedule for starting, tapering or stopping anything, and treats decisions about a prescription medicine as belonging with the prescriber who wrote it. --- Brand My Peptides is a reference desk on the metabolic-peptide literature: it records what each trial measured, at what point in the trial, and what the withdrawal arms recorded afterwards — it brands nothing, sells nothing, prescribes nothing and advises no one.